0.40Open0.40Pre Close0 Volume2 Open Interest2.50Strike Price0.00Turnover328.11%IV53.44%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.40Extrinsic Value100Contract SizeAmericanOptions Type-0.1315Delta0.0549Gamma11.28Leverage Ratio-0.0164Theta-0.0006Rho-1.48Eff Leverage0.0025Vega
MaxCyte Stock Discussion
NEWS
MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development
MaxCyte has signed a strategic platform license agreement with Legend Biotech to accelerate the discovery and development of cell therapies. Under this non-exclusive worldwide license, Legend Biotech will use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform for various cell types, including T cells and NK cells. MaxCyte will receive an...
Larger Image: tradingview.com...
$MaxCyte(MXCT.US)$
• $Antares Pharma(ATRS.US)$ +48.7% (to be acquired by Halozyme (HALO) for $5.60 per share)
• $Sierra Oncology(SRRA.US)$ +37.9% (acquired by GSK for $55 per share)
• $Amryt Pharma(AMYT.US)$ +11.7% (announces positive long-term safety and efficacy data for Mycapssa (oral octreotide) from the 2nd Year of OPTIMAL open label extension study in acromegaly patients)
• $BriaCell Therapeutics(BCTX.US)$ +6% (presents development details of...
No comment yet